tbuckley/cabot-search huggingface dataset:
Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma
Authors: Ah Yeong Kim, Dong Hyun Sinn, Woo Kyoung Jeong, Young Kon Kim, Tae Wook Kang, Sang Yun Ha, Chul Keun Park, Gyu Seong Choi, Jong Man Kim, Choon Hyuck David Kwon, Jae-Won Joh, Min-Ji Kim, Insuk Sohn, Sin-Ho Jung, Seung Woon Paik, Won Jae Lee
Journal: Journal of Hepatology (2018)
Cognitive Computational Neuroscience: A New Conference for an Emerging Discipline
Authors: Thomas Naselaris, Danielle S. Bassett, Alyson K. Fletcher, Konrad Kording, Nikolaus Kriegeskorte, Hendrikje Nienborg, Russell A. Poldrack, Daphna Shohamy, Kendrick Kay
Journal: Trends in Cognitive Sciences (2018)
Artesunate shows potent anti-tumor activity in B-cell lymphoma
Authors: Thea Kristin Våtsveen, Marit Renée Myhre, Chloé Beate Steen, Sébastien Wälchli, Ole Christian Lingjærde, Baoyan Bai, Pierre Dillard, Theodossis A. Theodossiou, Toril Holien, Anders Sundan, Else Marit Inderberg, Erlend B. Smeland, June Helen Myklebust, Morten P. Oksvold
Journal: Journal of Hematology & Oncology (2018)

Although chemo-immunotherapy has led to an improved overall survival for most B-cell lymphoma types, relapsed and refractory disease remains a challenge. The malaria drug artesunate has previously been identified as a growth suppressor in some cancer types and was tested as a new treatment option in B-cell lymphoma.We included artesunate in a cancer sensitivity drug screen in B lymphoma cell lines. The preclinical properties of artesunate was tested as single agent in vitro in 18 B-cell lymphoma cell lines representing different histologies and in vivo in an aggressive B-cell lymphoma xenograft model, using NSG mice. Artesunate-treated B lymphoma cell lines were analyzed by functional assays, gene expression profiling, and protein expression to identify the mechanism of action.Drug screening identified artesunate as a highly potent anti-lymphoma drug. Artesunate induced potent growth suppression in most B lymphoma cells with an IC50 comparable to concentrations measured in serum from artesunate-treated malaria patients, while leaving normal B-cells unaffected. Artesunate markedly inhibited highly aggressive tumor growth in a xenograft model. Gene expression analysis identified endoplasmic reticulum (ER) stress and the unfolded protein response as the most affected pathways and artesunate-induced expression of the ER stress markers ATF-4 and DDIT3 was specifically upregulated in malignant B-cells, but not in normal B-cells. In addition, artesunate significantly suppressed the overall cell metabolism, affecting both respiration and glycolysis.Artesunate demonstrated potent apoptosis-inducing effects across a broad range of B-cell lymphoma cell lines in vitro, and a prominent anti-lymphoma activity in vivo, suggesting it to be a relevant drug for treatment of B-cell lymphoma.
Particularités et innocuité de la cholangio-pancréatografie rétrograde endoscopique thérapeutique chez le sujet âgé
Authors: H Hassine, H Elloumi, D Trad, M Sabbah, N Bibani, D Gargouri, A Ouakaa-Kchaou, J Kharrat
Journal: Endoscopy (2018)

La cholangio-pancréatografie rétrograde endoscopique (CPRE) thérapeutique joue un rôle important dans la prise en charge des différentes pathologies du carrefour bilio-pancréatique. Les données concernant sa faisabilité et sa sécurité chez le sujet âgé restent limitées. Il est ainsi raisonnable d'étudier ce sujet d'autant plus le nombre croissant des examens réalisés chez cette population de patients.
Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis
Authors: Benjamin Lockshin, Yevgeniy Balagula, Joseph F. Merola
Journal: Journal of the American Academy of Dermatology (2018)

In addition to being recognized as a chronic inflammatory disease that manifests in the skin, psoriasis is increasingly understood to be a systemic disease that causes immune dysregulation throughout the body. The systemic nature of psoriasis is evidenced by the higher burden of comorbidities and shorter life expectancies of patients with psoriasis, particularly those with early-onset and severe disease. Notably, psoriasis is associated with an increased risk for cardiovascular disease, which is the most common cause of morbidity and mortality in patients with psoriasis. In this review, we examine the association between psoriasis and cardiovascular disease and specifically focus on the role of interleukin 17-mediated inflammation as a potential mechanistic link between psoriasis and cardiovascular disease. Moreover, we describe potential treatment approaches to reduce the burden of cardiovascular disease in patients with psoriasis and discuss the clinical importance of the association of these 2 diseases with respect to patient management and education.
Prognostic significance of elevated troponin I after valve heart surgery
Authors: Roberto C Aragão, Roney O Sampaio, Márcio Sommer Bittencourt, Antonio S Lopes, Tarso A Accorsi, Vitor E Rosa, João R Fernandes, Guilherme S Spina, Ludhmila A Hajjar, Flavio Tarasoutchi
Journal: Circulation (2015)
Macromolecular prodrugs of ribavirin: Polymer backbone defines blood safety, drug release, and efficacy of anti-inflammatory effects
Authors: Kaja Zuwala, Camilla F. Riber, Kaja Borup Løvschall, Anna H.F. Andersen, Lise Sørensen, Paulina Gajda, Martin Tolstrup, Alexander N. Zelikin
Journal: Journal of Controlled Release (2018)
Clostridium innocuum is a vancomycin-resistant pathogen that may cause antibiotic-associated diarrhoea
Authors: J.-H. Chia, T.-S. Wu, T.-L. Wu, C.-L. Chen, C.-H. Chuang, L.-H. Su, H.-J. Chang, C.-C. Lu, A.-J. Kuo, H.-C. Lai, C.-H. Chiu
Journal: Clinical Microbiology and Infection (2018)
Evaluation of a new multiplex PCR assay (ParaGENIE G-Amoeba Real-Time PCR kit) targeting Giardia intestinalis, Entamoeba histolytica and Entamoeba dispar/Entamoeba moshkovskii from stool specimens: evidence for the limited performances of microscopy-based approach for amoeba species identification
Authors: F. Morio, S. Valot, A. Laude, G. Desoubeaux, N. Argy, C. Nourrisson, C. Pomares, M. Machouart, Y. Le Govic, F. Dalle, F. Botterel, N. Bourgeois, E. Cateau, M. Leterrier, F. Jeddi, M. Gaboyard, P. Le Pape
Journal: Clinical Microbiology and Infection (2018)
Downregulation of Circulating miRs-206-3p and -381-3p May Serve As Putative Serum Biomarkers for Detection of 4,4’-Methylene Diphenyl Diisocyanate Exposure
Authors: Chen-Chung Lin, Brandon F. Law, Paul D. Siegel, Justin M. Hettick
Journal: Journal of Allergy and Clinical Immunology (2018)
Inspiratory muscle training in stable COPD patients: enough is enough?
Authors: Nicolino Ambrosino
Journal: European Respiratory Journal (2018)

Inspiratory muscle dysfunction is a common finding in patients suffering from chronic obstructive pulmonary disease (COPD), contributing with other factors to dyspnoea and reduced exercise tolerance [1]. Pulmonary rehabilitation programmes (PRPs) including whole-body exercise training improve symptoms, exercise capacity and health-related quality of life (HRQL), and are recommended in all stages of COPD [2, 3]. In 1976, Leith and Bradley [4] were the first to show that the principles of training could be applied also to respiratory muscles: healthy strength trainers significantly increased their maximal static inspiratory and expiratory pressures. Endurance trainers increased their maximal voluntary ventilation but not maximal static pressures. There is enough research to draw conclusions on IMT in COPD patients <http://ow.ly/igyD30h9kRE>
I often read in the requirements for a post “MRCP or equivalent.” What is meant by equivalent?
Authors: Alan Watson
Journal: BMJ (2004)

<i>Got a career or related problem that needs answering? Can9t find the right person to point you in the right direction? Log on to the Advice Zone (www.bmjcareers.com/advicezone) for reliable medical careers advice. You can post a question or see if one of our 300 advisers has already answered a similar question. Here is a selection of questions and answers posted on the site.</i>
Overall survival of PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).
Authors: J. Randolph Hecht, Aung Naing, Gerald Steven Falchook, Manish R. Patel, Jeffrey R. Infante, Raid Aljumaily, Deborah Jean Lee Wong, Karen A. Autio, Zev A. Wainberg, Milind M. Javle, Johanna C. Bendell, Shubham Pant, Annie Hung, Peter Van Vlasselaer, Martin Oft, Kyriakos P. Papadopoulos
Journal: Journal of Clinical Oncology (2018)

374 Background: The therapeutic options for 2 nd line therapy PDAC remain unsatisfying with 5-FU/LV plus oxaliplatin or nal-irinotecan resulting in a mOS of 5-6 mo. PDAC has been largely refractory to immune-oncology approaches and CD8 T cells are rare in most PDAC. AM0010 stimulates survival, expansion and cytotoxicity of intratumoral CD8+ T cells. Immune activation, durable stable disease and a 1yr survival of 22.5% was seen in salvage PDAC patients (pts) receiving AM0010 alone. AM0010 has synergistic anti-tumor activity with 5-FU/LV or oxaliplatin in preclinical models. Here we report on the safety, efficacy and overall survival of AM0010 + FOLFOX as 2 nd and later line treatment in PDAC. Methods: PDAC progressing on a median of 2 prior therapies (range 1-5) were treated with AM0010 (5ug/kg SQ, qd) + FOLFOX (n = 21). The safety population (n = 25) included also 4 pts with prior oxaliplatin / 5-FU. The survival population included patients without prior platinum containing regimen. Tumor responses were assessed with irRC. Biomarkers evaluated the activation and clonality of peripheral T cells. Archival tumor tissues were evaluated for tumor infiltration by CD8 T cells, by whole exome sequencing and mRNA analysis. Results: AM0010 + FOLFOX, was generally well tolerated. G3/4 TrAEs included thrombocytopenia (52%), anemia (44%), neutropenia (36%) and fatigue (12%). Most cytopenias had a short duration, reaching retreatment criteria within 2-5 days after dose interruption. Dosing AM0010 for 5 days followed by a 2 days dose holiday avoided G3/4 cytopenias. As of 08/11/2017, 2 patients have remained on treatment for &gt; 1 year. Of 19 evaluable pts, 2 had an irCR, 1 had irPR with 100% reduction in tumor burden, ORR is 15.8%, DCR is 78.9%. With median follow-up of 19.2 months (range 13.4-24.1), mPFS was 3.5 mo, mOS was 10.2 mo and 1-year survival was 43%. Transcriptional profiling and CD8 T cells in the archival tumor tissue may identify patients with longer OS. Conclusions: AM0010 in combination with FOLFOX is well tolerated in patients with metastatic PDAC. Immune activation, mOS and 1 year survival are encouraging in this advanced PDAC population. This regimen is currently being studied in a phase 3 trial Clinical trial information: NCT02009449.
Bendamustine‐based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers
Authors: Sylvain P. Chantepie, Sylvain Garciaz, Emmanuelle Tchernonog, Frederic Peyrade, Marie‐Virginie Larcher, Momar Diouf, Luc‐Mathieu Fornecker, Roch Houot, Thomas Gastinne, Carole Soussain, Sandra Malak, Richard Lemal, Caroline Delette, Ahmad Ibrahim, Anne‐Claire Gac, Emilie Reboursière, Jean‐Pierre Vilque, Mohamed‐Amine Bekadja, Rene‐Olivier Casasnovas, Remy Gressin, Stéphanie Guidez, Diane Coso, Charles Herbaux, Ibrahim Yakoub‐Agha, Krimo Bouabdallah, Eric Durot, Gandhi Damaj
Journal: American Journal of Hematology (2018)

Abstract Carmustine shortage has led to an increase use of alternative conditioning regimens prior to autologous stem cell transplantation for the treatment of lymphoma, including Bendamustine‐based (BeEAM). The aim of this study was to evaluate the safety of the BeEAM regimen in a large cohort of patients. A total of 474 patients with a median age of 56 years were analyzed. The majority of patients had diffuse large B‐cell lymphoma (43.5%). Bendamustine was administered at a median dose of 197 mg/m 2 /day (50‐250) on days‐7 and −6. The observed grade 1‐4 toxicities included mucositis (83.5%), gastroenteritis (53%), skin toxicity (34%), colitis (29%), liver toxicity (19%), pneumonitis (5%), and cardiac rhythm disorders (4%). Nonrelapse mortality (NRM) was reported in 3.3% of patients. Acute renal failure (ARF) was reported in 132 cases (27.9%) (G ≥2; 12.3%). Organ toxicities and death were more frequent in patients with post conditioning renal failure. In a multivariate analysis, pretransplant chronic renal failure, bendamustine dose &gt;160 mg/m 2 and age were independent prognostic factors for ARF. Pretransplant chronic renal failure, hyperhydration volume, duration of hyperhydration, and etoposide dose were predictive factors of NRM. A simple, four‐point scoring system can stratify patients by levels of risk for ARF and may allow for a reduction in the bendamustine dose to avoid toxicity. Drugs shortage may have dangerous consequences. Prospective, comparative studies are needed to confirm the toxicity/efficacy extents from this conditioning regimen compared to other types of high dose therapy.
Oversedation of a Patient With Obstructive Sleep Apnea Prior to Imaging
Authors: Eddie Blay, Cynthia Barnard, Karl Y. Bilimoria
Journal: JAMA (2018)

This JAMA Performance Improvement article uses the case of a patient with obstructive sleep apnea who experienced cardiac arrest after sedation for magnetic resonance imaging to discuss proper handling and avoidance of oversedation in high-risk patients.
Abstract P3-03-06: Telomerase polymorphism and breast cancer
Authors: MM Alvares, KS Rodrigues, JN Matos, DM Oliveira
Journal: Cancer Research (2018)

Abstract Introduction: Telomerase is an enzyme responsible for telomere maintenance in almost all human cancer cells, but generally not expressed in somatic ones. The minimum essential components of telomerase are the catalytic subunit, telomerase reverse transcriptase (TERT), and a non- coding RNA (TERC); TERT reverse transcribes telomere DNA using TERC as the template (1). Given the fundamental role of TERT in oncogenesis, polymorphisms of genes related to telomerase may influence the expression levels of this enzyme, influencing the host's susceptibility to tumor progression and metastasis [2,3]. Some studies have linked these polymorphisms with susceptibility and/or survival of patients with breast cancer [2,4,5,6]. In this work, we analyzed a region in the second intron of the gene TERT, located in chromosome 5p15.33, by sequencing, in order to find mutations associated with clinical aspects. The DNA of 65 patients with breast cancer were evaluated. Methodology: The population consisted of breast cancer patients who accepted to participate in the study, attended from March 2015 to September 2016 at a public hospital (HUB) and a private center for cancer treatment (Cettro®), both in Brasília city – Brazil. Standard DNA extraction from blood samples was performed by dehydration and precipitation with saturated NaCl solution. The concentration and purity of the DNA were determined by spectrophotometry using the NanoDrop One equipment® (Themo Scientific, Madison, USA). The region of interest was amplified by conventional PCR. The primer sequences were: F: 5'-ATG CGA CAG TTC GTG GCT CA-3 'and R: 5'-ATC CCC TGG CAC TGG ACG TA-3'. The sequencing was performed in the AB 3500 Genetic Analyzer® (Applied Biosystems). Data were analyzed by using software Chromas Lite ® (2.01, Technelysium Pty Ltd.) and the BLAST (NCBI - http://blast.ncbi.nlm.nih.gov/Blast.cgi). GraphPad Prism software version 7.02 was used for statistical analyzes. Results and Conclusion: A total of 65 patients were selected for DNA analysis. We identified a recurrent mutation (C&amp;gt;T) among them. The allelic frequencies were 0,79 for C and 0,21 for T. Only three patients had genotype TT, but 21 were heterozygous (CT). This polymorphism was significantly associated with tumor grade, the presence of T allele were implicated in more aggressive (grade 3) tumors (p=0.028, chi-square test). Those patients whith genotype CT were at greater risk them others whith CC genotype of having high grade (3) breast tumors (odds ratio = 6.13, 95% confidence interval 1.46, 25.74; relative risk 1.9, 95% confidence interval 1.02, 3.59). Citation Format: Alvares MM, Rodrigues KS, Matos JN, Oliveira DM. Telomerase polymorphism and breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-03-06.
PHYSICIAN JUDGMENT MORE ACCURATE THAN DIAMOND-FORRESTER RISK SCORE IN PREDICTING OBSTRUCTIVE CAD AND ADVERSE CARDIAC EVENTS IN PATIENTS WITH CHEST PAIN: INSIGHTS FROM THE PROMISE TRIAL
Authors: Christopher Fordyce, C.L. Hill, Adrian Coles, Kerry Lee, Daniel Mark, Udo Hoffmann, Manesh Patel, Pamela S. Douglas
Journal: Journal of the American College of Cardiology (2018)
INTERVENTION TO ALTER DIETARY CONSUMPTION TO A MEDITERRANEAN DIET IN AN AMERICAN CARDIOLOGY PATIENT POPULATION: A RANDOMIZED CONTROLLED TRIAL OF COACHING DELIVERED VIA SMARTPHONE APP VERSUS TRADITIONAL COUNSELING
Authors: Brian Choi, Tania Dhawan, Kelli Metzger, Lorraine Marshall, Awdah Akbar, Tushina Jain, Heather Young, Richard Katz
Journal: Journal of the American College of Cardiology (2018)
Bronchodilator reversibility in COPD: the roguish but harmless little brother of airway hyperresponsiveness?
Authors: EF Hansen, Jørgen Vestbo
Journal: American Journal of Respiratory and Critical Care Medicine (2005)

Airway hyperresponsiveness (AHR) in chronic obstructive pulmonary disease (COPD) is well described in an epidemiological context with rather consistent results. It is known that AHR is a negative prognostic marker, associated with an accelerated decline in forced expiratory volume in one second (FEV1) 1–3 and probably also associated with an increase in mortality 4. The presence of AHR in individual subjects is almost constant. Thus, in the Lung Health Study (LHS), where responsiveness to methacholine was measured at two time points 5-yrs apart, <17% of the participants changed responsiveness by ≥2 concentrations 5. Smoking cessation is reported to have a beneficial effect on AHR 5, and smokers with high levels of AHR seem to gain more from smoking cessation in terms of FEV1 6.

Even if a lot of the “hows” for AHR in COPD are known, the “whys” have still not been answered. It is not known if AHR truly denotes a susceptibility to smoking, in line with the Dutch hypothesis, or if it is a mere reflection of the progression in COPD. AHR is, unlike in the case of asthma, resistant to current treatments, and extremely little is known of the underlying airway biology associated with AHR in COPD.

Bronchodilator reversibility (BDR) in COPD has also been extensively studied, but with more complex and confusing results than …
SLEEP DEPRIVATION IN CARDIOLOGY: A MULTIDISCIPLINARY SURVEY
Authors: Angie Lobo, Yader Sandoval, M. Nicholas Burke, Ivan Chavez, Mario Gossl, Timothy Henry, Daniel Lips, Steven Bradley, Michael Mooney, Anil Poulose, Paul Sorajja, Jay Traverse, Yale Wang, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2018)
Is the T Follicular Regulatory:Follicular Helper T Cell Ratio in Blood a Biomarker for Ectopic Lymphoid Structure Formation in Sjögren's Syndrome? Comment on the Article by Fonseca et al
Authors: Gwenny M. Verstappen, Uzma Nakshbandi, Esther Mossel, Erlin A. Haacke, Bert van der Vegt, Arjan Vissink, Hendrika Bootsma, Frans G. M. Kroese
Journal: Arthritis & Rheumatology (2018)

We read with great interest the article by Fonseca et al (1), that was published in a recent issue of Arthritis & Rheumatology. The authors elegantly showed that T follicular regulatory (Tfr) cells were enriched in blood as well as in matched minor salivary gland (MSG) biopsies from patients with primary Sjogren's syndrome (pSS). They also showed that the Tfr/Tfh ratio in blood was increased in pSS compared to non-SS sicca patients. Interestingly, this Tfr/Tfh ratio in blood correlated with ectopic lymphoid structure formation in MSG tissue. To our opinion the authors did, however, not show a direct correlation between aberrant Tfr/Tfh ratios and ectopic lymphoid structure formation among pSS patients. In essence their study showed that in pSS patients the Tfr/Tfh ratio in blood was correlated with numbers of infiltrating lymphocytes, as assessed by flow cytometric analysis of MSG cell suspensions. Additionally, the authors showed that the Tfr/Tfh ratio in blood was increased in patients with focal sialoadenitis (FSA) (defined in their study as a focus score ≥1), compared to patients without FSA. Of note, this comparison was made irrespective of a diagnosis of pSS, which implicated that the majority of patients without FSA were non-SS sicca patients. This article is protected by copyright. All rights reserved.
MicroRNA dysregulation as a prognostic biomarker in wild-type RAS/RAF/PTEN/PI3 metastatic colon cancer treated with anti-EGFR therapeutics
Authors: S. Aksoy, O. Kanat, B. Tunca, H. Ertas, N. Ugras, E. Ozturk, T. Yilmazlar, G. Cecener, U. Egeli, O. Yerci
Journal: Annals of Oncology (2018)
Association of changes in T regulatory cells (Treg) during nivolumab treatment with melanoma outcome.
Authors: Jeffrey S. Weber, Rupal Ramakrishnan, Andressa Laino, Anders E. Berglund, David Woods
Journal: Journal of Clinical Oncology (2017)

3031 Background: PD-1 blocking antibodies have significant efficacy in the treatment of melanoma; however, many patients fail to respond and resistance mechanisms remain unknown. We addressed the role of T regs , an immunosuppressive T-cell population, in patient outcome after treatment with nivolumab. Methods: Peripheral blood mononuclear cells (PBMC) were obtained from patients on trials with nivolumab as adjuvant therapy for resected disease or as treatment for metastatic melanoma. To measure suppression, T regs were flow-sorted from PBMC and evaluated in allogeneic mixed lymphocyte reactions. T regs and conventional CD4 T-cells were evaluated for gene expression changes by RNA-sequencing. T reg percentages and phosphorylated STAT3 (pSTAT3) expression were evaluated by flow cytometry. The effects of PD-1 blockade with nivolumab were evaluated in vitro using T-cells from baseline patient PBMC samples. Results: T regs from responding patients or adjuvant patients without evidence of disease (NED) had reduced suppressive function post-nivolumab (p &lt; 0.05), but no changes were observed in relapsing/non-responding patients; their T regs were more suppressive than NED/responding T regs (p &lt; 0.001). NED T regs had unique gene expression changes and associated pathways post-nivolumab compared to relapsing patient T regs and conventional CD4 T-cells, including up-regulation of proliferation pathways (q &lt; 8e-19) and downregulation of oxidative phosphorylation (q &lt; 7e-5). NED T regs had upregulation of pSTAT3 expression post-nivolumab (p &lt; 0.05), which was not observed in relapsing patients. Evaluation of T regs from patients with active disease also showed upregulation of pSTAT3 in responders (p &lt; 0.05) but not non-responders. The relative increase in T reg pSTAT3 was associated with increased overall survival (R 2 = 0.49, p &lt; 0.05). In vitro assays using PD-1 blocking antibodies recapitulated the increase in pSTAT3 (p &lt; 0.05) and T reg percentages (p &lt; 0.001), which were diminished with the addition of a STAT3 inhibitor (p &lt; 0.01). Conclusions: These results demonstrate previously unknown roles of decreased T reg suppressive function and induction of STAT3 as biomarkers of patient’s outcome to nivolumab therapy.
ALL-CAUSE MORTALITY ANALYSIS OF THE PROTECT-AF AND PREVAIL STUDIES OF LEFT ATRIAL APPENDAGE CLOSURE
Authors: William Whang, David Holmes, Marc Miller, Marie-Noelle Langan, Subbarao Choudry, Aamir Sofi, Jacob Koruth, Srinivas Dukkipati, Vivek Yerrapu Reddy
Journal: Journal of the American College of Cardiology (2018)